8-Azaadenosine

Research use only, not for human use.

8-Azaadenosine is a potent ADAR1 inhibitor and an A-to-I editing inhibitor.

8-Azaadenosine is a potent ADAR1 inhibitor and an A-to-I editing inhibitor. It blocks RNA editing and inhibits proliferation, 3D growth, invasion, and migration in thyroid cancer cells.

8-Azaadenosine targets ADAR (adenosine deaminases acting on double-stranded RNA) activity only and does not affect ADAR1 mRNA levels. 8-Azaadenosine (10-25 nM) restores let-7 miRNA biogenesis commensurate with a reduction in ADAR1 expression, RNA editing activity and LIN28B expression in JAK2/BCR-ABL1 transduced progenitors after two weeks in stromal co-culture. 8-Azaadenosine (10, 100 nM) shows no effect on BCR-ABL and JAK2 signaling, as demonstrated by qRT-PCR analysis and p-CRKL and p-STAT5a Western blot analysis. 8-Azaadenosine (0.1, 0.5, 1, 2 μM; 5 days) decreases cell viability/proliferation in a dose-dependent manner in TPC1 and Cal62 cells. 8-Azaadenosine (1, 2 μM; 16 hours) impedes invasion and migration of TPC1 and Cal62 cells. 8-Azaadenosine (1, 2 μM) inhibits the editing activity in TPC1 and Cal62 cells. By contrast, ADAR1 mRNA levels remains stable in both cells lines.

——

——

Apoptosis

Adenosine Receptor

Adenosine Deaminase

——

——

10299-44-2

268.23

C9H12N6O4

>98% (HPLC)

DMSO:250 mg/mL (932.04 mM; Need ultrasonic)

Nc1c2nnn([C@@H]([C@@H]3O)O[C@H](CO)[C@H]3O)c2ncn1

——

(-20℃)

With Ice Pack

≥ 2 years